CLINICAL TRIALS PROFILE FOR LINIFANIB

Clinical Trials for Linifanib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00733187 ↗	Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869	Completed	Genentech, Inc.	Phase 1	To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
NCT00733187 ↗	Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869	Completed	AbbVie (prior sponsor, Abbott)	Phase 1	To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
NCT01009593 ↗	Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)	Terminated	Abbott	Phase 3	The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
NCT01114191 ↗	A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)	Completed	Abbott	Phase 1	This is a phase 1, open-label study designed to determine the interaction of ketoconazole with ABT-869.
NCT01225302 ↗	A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)	Completed	Abbott	Phase 1	The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in the subjects as first-line treatment.
NCT01225302 ↗	A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)	Completed	AbbVie	Phase 1	The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in the subjects as first-line treatment.
NCT01286974 ↗	A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.	Terminated	Abbott	Phase 1	A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.

Clinical Trial Conditions for Linifanib

Condition Name

Condition Name
Intervention	Trials
Advanced Solid Tumors	5
Hepatocellular Carcinoma	1
Recurrent Rectal Cancer	1
Advanced or Metastatic Solid Tumors	1

Condition MeSH

Condition MeSH
Intervention	Trials
Neoplasms	5
Carcinoma, Hepatocellular	2
Carcinoma	2
Neoplasms, Glandular and Epithelial	1

Clinical Trial Locations for Linifanib

Trials by Country

Trials by Country
Location	Trials
United States	28
Japan	2
Hong Kong	1
Bangladesh	1
Argentina	1

Trials by US State

Trials by US State
Location	Trials
Michigan	4
New Hampshire	3
Washington	2
Texas	2
Maryland	2

Clinical Trial Progress for Linifanib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	6
Terminated	4
Recruiting	1

Clinical Trial Sponsors for Linifanib

Sponsor Name

Sponsor Name
Sponsor	Trials
Abbott	8
AbbVie	2
AbbVie (prior sponsor, Abbott)	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	13
Other	2